1 résultat
A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non–small cell lung cancer
Auteurs / Authors
Duruisseaux M, Swalduz A, Mazieres J, Barlesi F, Amour E, Morin F, Westeel V
Journal / Conference
ASCO
Année / Year
2022
PMID / session
Etude IFCT